Attached files
file | filename |
---|---|
8-K - FORM 8-K - BRAINSTORM CELL THERAPEUTICS INC. | v305656_8k.htm |
March 12, 2012 |
BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis
Proposed Trial Will Build on NurOwn™ Platform to Meet Unmet Needs of Patients with Neurodegenerative Disorders
NEW YORK & PETACH TIKVAH, ISRAEL--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of adult stem cell technologies and CNS therapeutics, announces plans to initiate a preclinical study assessing the efficacy of its NurOwn™ stem cell technology in patients with Multiple Sclerosis (MS). Positive proof-of-concept results for MS have been confirmed in a set of in-vitro and in-vivoexperiments, and the Company is working to advance MS into preclinical developmentin Q2 2012.
Based on initial promising pre-clinical data published by the Company's Chief Scientist, Prof. Daniel Offen of Tel Aviv University, BrainStorm has decided to explore MS as an additional indication for its NurOwn technology. The Company will draw plans to initiate pre-clinical safety trials, after which it will seek a leading medical center specializing in MS for clinical trials.
“We have been focused on growing our pipeline of indications using our NurOwn™ stem-cell technology,” commented Dr. Adrian Harel, Acting CEO of BrainStorm Cell Therapeutics. “As we continue our ongoing trials to evaluate the safety, tolerability and therapeutic effects of NurOwn™ in ALS patients, we have determined through positive preliminary animal data that MS will be the next indication to pursue using our technology.”
About NurOwn™
The NurOwn™ technology processes adult human mesenchymal stem cells that are present in bone marrow and are capable of self-renewal as well as differentiation into many cell types. The research team is among the first to have successfully achieved the in-vitro differentiation of adult bone marrow cells (animal and human) into cells capable of releasing neurotrophic factors, such as glial-derived neurotrophic factor (GDNF), by means of a specific differentiation-inducing culture medium.
About Multiple Sclerosis (MS) |
About BrainStorm Cell Therapeutics
Inc.
Safe Harbor Statement
Contacts:
|
2 |